<?xml version="1.0" encoding="UTF-8"?>
<p>Patients were monitored for adverse events (AEs) continuously for the duration of the study. In addition, clinical laboratory measurements were performed during every cycle, including a complete blood count (CBC) with differential, serum chemistry, and urinalysis. Adverse events and laboratory values were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03 
 <xref rid="cam41388-bib-0002" ref-type="ref">2</xref>.
</p>
